Top

Published in:

01-09-2013 | Co-infections (MA Jacobson, Section Editor)

Impact of Community-Associated Methicillin Resistant Staphylococcus aureus on HIV-Infected Patients

Authors: Joanna Cole, Kyle Popovich

Published in: Current HIV/AIDS Reports | Issue 3/2013

Abstract

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as an increasingly important pathogen, causing infections in persons who have no significant healthcare exposures. Persons with human immunodeficiency virus (HIV) infection have been disproportionately affected by CA-MRSA, with increased colonization and infection documented. Several factors are likely involved in the increased CA-MRSA burden observed among HIV-infected patients, including immune factors as well as healthcare and community exposures. Proposed community exposures that have been associated with increased CA-MRSA risk include substance abuse, incarceration, geographic area of residence, and social networks. This article explores these associations and reviews the current knowledge of the epidemiology, pathogenesis, clinical manifestations, and treatment of CA-MRSA in HIV-infected persons.

Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436–44.PubMedCrossRef

Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593–8.PubMedCrossRef

Anon. Methicillin-Resistant Staphylococcus aureus infections in correctional facilities --- Georgia, California, and Texas, 2001–2003.

Baillargeon J, Kelley MF, Leach CT, Baillargeon G, Pollock BH. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis. 2004;38(9):e92–5.PubMedCrossRef

Kazakova SV, Hageman JC, Matava M, et al. A clone of Methicillin-Resistant Staphylococcus aureus among professional football players. N Engl J Med N Engl J Med. 2005;352(5):468–75.CrossRef

Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004;39(10):1446–53.PubMedCrossRef

Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, CA, in 2002. J Clin Microbiol. 2004;42(9):4050–3.PubMedCrossRef

Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100–7.PubMedCrossRef

Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by Community-Associated Methicillin-Resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445–53.PubMedCrossRef

10.

Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis. 2006;42(5):647–56.PubMedCrossRef

11.

Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis. 2004;39(7):971–9.PubMedCrossRef

12.

Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-Resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.PubMedCrossRef

13.

• Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis. 2010;50(7):979–987. This study documented the disproportionate impact CA-MRSA has had on HIV-infected patients in comparison to HIV-negative patients. PubMedCrossRef

14.

Shet A, Mathema B, Mediavilla JR, et al. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis. 2009;200(1):88–93.PubMedCrossRef

15.

Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148(4):249–57.PubMedCrossRef

16.

Anon. CDC - MRSA and the workplace - NIOSH workplace safety and health topic.

17.

Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(5):752–60.PubMedCrossRef

18.

Popovich KJ, Weinstein RA. Commentary: the graying of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2009;30(1):9–12.PubMedCrossRef

19.

Popovich K, Weinstein R, Aroutcheva A, Rice T, Hota B. Community-associated Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSIs)—Evolving Epidemiology? In: San Diego: Society for Healthcare Epidemiology of America; 2009.

20.

McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41(11):5113–20.PubMedCrossRef

21.

Diep BA, Sensabaugh GF, Somboonna N, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol. 2004;42(5):2080–4.PubMedCrossRef

22.

• Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(1):43–54. In this meta-analysis of the published data on the association of PVL-producing S. aureus and disease manifestations, PVL-producing S. aureus infections were more likely to be associated with SSTIs rather than invasive disease and were not associated with worse outcomes, suggesting that PVL is not the main determinant of disease severity. PubMedCrossRef

23.

Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006;367(9512):731–9.PubMedCrossRef

24.

Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007;13(12):1405–6.PubMedCrossRef

25.

Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS. 2007;18(8):521–6.PubMedCrossRef

26.

Hidron AI, Moanna A, Rimland D. The rise and fall of methicillin-resistant Staphylococcus aureus infections in HIV patients. AIDS. 2011;25(7):1001–3.PubMedCrossRef

27.

Furuno JP, Johnson JK, Schweizer ML, et al. Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study. BMC Infect Dis. 2011;11:298.PubMedCrossRef

28.

Ramsetty SK, Stuart LL, Blake RT, Parsons CH, Salgado CD. Risks for methicillin-resistant Staphylococcus aureus colonization or infection among patients with HIV infection. HIV Med. 2010;11(6):389–94.PubMed

29.

Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr. 2005;40(2):155–60.PubMedCrossRef

30.

Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008;49(2):231–3.PubMedCrossRef

31.

Crum-Cianflone N, Weekes J, Bavaro M. Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDS. 2009;23(7):499–502.PubMedCrossRef

32.

Skiest D, Brown K, Hester J, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 2006;7(6):361–8.PubMedCrossRef

33.

Szumowski JD, Wener KM, Gold HS, et al. Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with men. Clin Infect Dis. 2009;49(1):118–21.PubMedCrossRef

34.

Shastry L, Rahimian J, Lascher S. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections in men who have sex with men in New York City. Arch Intern Med. 2007;167(8):854–7.PubMedCrossRef

35.

Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10(3):505–20.PubMed

36.

• Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect. 2010;16(5):425–431. This study of S. aureus colonization at different anatomic sites in patients with an acute SSTI is one of the first reports to suggest that CA-MRSA may have distinct colonization patterns. In patients with acute S. aureus SSTIs, extra-nasal colonization with CA-MRSA was more common than patients with MSSA infections or HA-MRSA infections. PubMedCrossRef

37.

Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197(9):1226–34.PubMedCrossRef

38.

•• Popovich KJ, Smith KY, Khawcharoenporn T, et al. Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients. Clin Infect Dis. 2012;54(9):1296–1303. Outpatient study demonstrating higher prevalence of CA-MRSA nares colonization in HIV-infected patients compared to HIV-negative. Within HIV-infected patients there is variation in prevalence of CA-MRSA colonization, with women and individuals who were recently incarcerated having the highest prevalence. PubMedCrossRef

39.

Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr. 2008;48(5):567–71.PubMedCrossRef

40.

Peters PJ, Brooks JT, Limbago B, et al. Methicillin-resistant Staphylococcus aureus colonization in HIV-infected outpatients is common and detection is enhanced by groin culture. Epidemiol Infect. 2010:1–11.

41.

Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344(1):11–6.CrossRef

42.

Hota B, Ellenbogen C, Hayden MK, et al. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch Intern Med. 2007;167(10):1026–33.PubMedCrossRef

43.

• Popovich KJ, Hota B, Aroutcheva A, et al. Community-associated methicillin-resistant staphylococcus aureus colonization burden in HIV-infected patients. Clin Infect Dis. 2013 Apr;56(8):1067-74. Prospective evaluation for CA-MRSA colonization at multiple anatomic sites at time of admission for HIV-infected and HIV-negative patients found that HIV-infected patients are more likely to have extra-nasal colonization with CA-MRSA, with 38 % of colonized patients having exclusive extra-nasal colonization with MRSA. PubMedCrossRef

44.

Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005;40(10):1529–34.PubMedCrossRef

45.

Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun. 2010;78(1):32–8.PubMedCrossRef

46.

Fischer-Stabauer M, Boehner A, Eyerich S, et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol. 2012;22(6):781–4.PubMed

47.

El Hed A, Khaitan A, Kozhaya L, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis. 2010;201(6):843–54.PubMedCrossRef

48.

Burkey MD, Wilson LE, Moore RD, et al. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med. 2008;9(10):858–62.PubMed

49.

Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(3):410–3.PubMedCrossRef

50.

Anon. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison--Mississippi, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(42):919–22.

51.

David MZ, Mennella C, Mansour M, Boyle-Vavra S, Daum RS. Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: risk factors and recurrence rates. J Clin Microbiol. 2008;46(10):3222–7.PubMedCrossRef

52.

Lowy FD, Aiello AE, Bhat M, et al. Staphylococcus aureus colonization and infection in New York State prisons. J Infect Dis. 2007;196(6):911–8.PubMedCrossRef

53.

Anon. Health status of soon-to-be-released inmates.

54.

Spaulding AC, Seals RM, Page MJ, et al. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558.PubMedCrossRef

55.

Hartley DM, Furuno JP, Wright MO, Smith DL, Perencevich EN. The role of institutional epidemiologic weight in guiding infection surveillance and control in community and hospital populations. Infect Control Hosp Epidemiol. 2006;27(2):170–4.PubMedCrossRef

56.

Farley JE, Ross T, Stamper P, et al. Prevalence, risk factors, and molecular epidemiology of methicillin-resistant Staphylococcus aureus among newly arrested men in Baltimore, Maryland. Am J Infect Control. 2008;36(9):644–50.PubMedCrossRef

57.

Popovich K, Hota B, Rice T, Aroutcheva A, Weinstein RA. Phenotypic prediction rule for community-associated methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2007;45(7):2293–5.PubMedCrossRef

58.

McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of resistance among USA300 Methicillin-Resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother. 2010;54(9):3804–11.PubMedCrossRef

59.

Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007;45(4):1350–2.PubMedCrossRef

60.

•• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55. Recently published guidelines for treatment of MRSA based on graded evidence and expert opinion. PubMedCrossRef

61.

Hammond SP, Baden LR. Management of skin and soft-tissue infection — polling results. N Engl J Med. 2008;359(15):e20. doi:10.1056/NEJMclde0806337.PubMedCrossRef

62.

Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51(11):4044–8.PubMedCrossRef

63.

Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23(2):123–7.PubMedCrossRef

64.

Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777–84.PubMedCrossRef

65.

Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(7):2628–30.PubMedCrossRef

66.

Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163(6):1279–85.PubMedCrossRef

67.

Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55(4):582–6.PubMedCrossRef

68.

Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398–402.PubMedCrossRef

69.

Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340–7.PubMedCrossRef

70.

Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.PubMedCrossRef

71.

Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for Bacteremia and Endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.PubMedCrossRef

72.

Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42(12):e108–10.PubMedCrossRef

73.

Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447–57.PubMedCrossRef

74.

Silverman JA, Mortin LI, Vanpraagh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149–52.PubMedCrossRef

75.

File Jr TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55 Suppl 3:S173–80.PubMedCrossRef

76.

Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis 2nd JS. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267–70.PubMedCrossRef

77.

Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346(24):1871–7.PubMedCrossRef

78.

Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.PubMedCrossRef

79.

Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother. 2007;51(10):3591–8.PubMedCrossRef

80.

Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis. 1999;180(3):896–9.PubMedCrossRef

81.

Gordon RJ, Chez N, Jia H, et al. The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals. J Acquir Immune Defic Syndr. 2010;55(4):466–72.PubMedCrossRef

82.

Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans’ Affairs hospital. Infect Control Hosp Epidemiol. 2000;21(7):459–64.PubMedCrossRef

83.

McGann P, Yoon I, Kwak MS, Summers A, et al. Detection of qacA/B in clinical isolates of Methicillin-Resistant Staphylococcus aureus from a regional healthcare network in the Eastern United States. Infect Control Hosp Epidemiol. 2011;32(11):1116–9.PubMedCrossRef

84.

• Daum RS, Spellberg B. Progress toward a staphylococcus aureus vaccine. Clin Infect Dis. 2011 Feb 15;54(4):560-7. Review of the efforts in S. aureus vaccine development to date and the specific pathogen and disease specific challenges involved in successful vaccine development.PubMedCrossRef

85.

Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346(7):491–6.PubMedCrossRef

86.

Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine. 2012;30(19):2921–7.PubMedCrossRef

87.

Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009;5(12):e1000703.PubMedCrossRef

88.

Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40(10):1429–34.PubMedCrossRef

89.

Bowen AC, Lilliebridge RA, Tong SYC, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol. 2012;50(12):4067–72.PubMedCrossRef

Title: Impact of Community-Associated Methicillin Resistant Staphylococcus aureus on HIV-Infected Patients
Authors: Joanna Cole
Kyle Popovich
Publication date: 01-09-2013
Publisher: Springer US
Published in: Current HIV/AIDS Reports / Issue 3/2013
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-013-0161-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Solid Organ Transplants in HIV-Infected Patients

Cardiovascular Disease and HIV Infection

Non-AIDS-defining Cancers Among HIV-Infected Patients

Combination HIV Prevention: The Value and Interpretation of Mathematical Models

Clostridium Difficile Infection in Patients with HIV/AIDS

Oral Health Considerations in HIV-Infected Children

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials